Blackstone agreed to acquire Nucleus Network, an operator of clinical research facilities, from Crescent Capital, an alternative investment firm. Financial terms were not disclosed. “We look forward to working with Cameron Johnson and his outstanding team to help Nucleus enter its next phase of growth, combining the domain expertise and scale of the Blackstone Life Sciences network with their talent, experience and enthusiasm. We’re proud to back one of Australia’s market leading phase one clinical trials providers as they look to expand and serve the rapidly growing biotech market both here and internationally," James Carnegie, Blackstone Head of Private Equity.